Literature DB >> 87670

Dissemination of tumour cells via LeVeen shunt.

B Maat, J Oosterlee, J A Spaas, H White, F B Lammes.   

Abstract

Entities:  

Mesh:

Year:  1979        PMID: 87670     DOI: 10.1016/s0140-6736(79)91779-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts.

Authors:  D Tarin; J E Price; M G Kettlewell; R G Souter; A C Vass; B Crossley
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-10

2.  Peritoneovenous shunting for intractable cirrhotic and cancerous ascites using different types of shunting tubes.

Authors:  K Akimaru; Y Ueda; T Shoji
Journal:  Jpn J Surg       Date:  1988-09

3.  Peritoneovenous shunts in malignant ascites.

Authors:  J H Helzberg; N J Greenberger
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

4.  Palliation of malignant ascites by the Denver peritoneovenous shunt.

Authors:  R Downing; J Black; C W Windsor
Journal:  Ann R Coll Surg Engl       Date:  1984-09       Impact factor: 1.891

5.  Peritoneovenous shunting in intractable ascites.

Authors:  G T Deans; R A Spence; G W Johnston
Journal:  Ulster Med J       Date:  1985-10

Review 6.  Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Clin Pharmacol       Date:  2013-10-03

7.  Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Int J Womens Health       Date:  2012-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.